Deutsche Bank AG reiterated their buy rating on shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in a research note released on Thursday, November 2nd. The brokerage currently has a $79.00 target price on the stock.
A number of other analysts have also weighed in on NBIX. Oppenheimer Holdings, Inc. reiterated an outperform rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, July 5th. BMO Capital Markets increased their target price on Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an outperform rating in a research note on Friday, August 4th. Cowen and Company reissued an outperform rating and set a $65.00 price target (up previously from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. BidaskClub raised Neurocrine Biosciences from a hold rating to a buy rating in a research report on Wednesday, August 9th. Finally, Piper Jaffray Companies set a $68.00 price objective on Neurocrine Biosciences and gave the company a buy rating in a research report on Thursday, August 24th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. The company has an average rating of Buy and a consensus target price of $78.88.
Neurocrine Biosciences (NASDAQ NBIX) traded down $2.13 during mid-day trading on Thursday, reaching $72.04. The company’s stock had a trading volume of 906,626 shares, compared to its average volume of 1,127,112. Neurocrine Biosciences has a 1-year low of $37.35 and a 1-year high of $75.98. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter in the previous year, the company posted ($0.43) EPS. sell-side analysts expect that Neurocrine Biosciences will post -1.74 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Receives “Buy” Rating from Deutsche Bank AG” was first posted by BBNS and is the property of of BBNS. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://baseballnewssource.com/markets/deutsche-bank-ag-reaffirms-buy-rating-for-neurocrine-biosciences-inc-nbix/1752987.html.
In other Neurocrine Biosciences news, insider Kyle Gano sold 24,818 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total transaction of $1,763,318.90. Following the transaction, the insider now owns 84,596 shares of the company’s stock, valued at $6,010,545.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Flint Obrien sold 52,817 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $57.50, for a total value of $3,036,977.50. Following the transaction, the insider now directly owns 101,790 shares in the company, valued at approximately $5,852,925. The disclosure for this sale can be found here. Insiders sold 140,810 shares of company stock worth $9,035,398 over the last ninety days. Corporate insiders own 4.80% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Teacher Retirement System of Texas raised its position in Neurocrine Biosciences by 0.8% in the second quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock valued at $320,000 after purchasing an additional 57 shares during the period. The Manufacturers Life Insurance Company raised its position in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares during the period. Utah Retirement Systems raised its position in Neurocrine Biosciences by 1.9% in the second quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock valued at $736,000 after purchasing an additional 300 shares during the period. Nuveen Asset Management LLC raised its position in Neurocrine Biosciences by 5.6% in the first quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock valued at $626,000 after purchasing an additional 763 shares during the period. Finally, Aperio Group LLC raised its holdings in shares of Neurocrine Biosciences by 3.7% in the 2nd quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock valued at $1,027,000 after buying an additional 789 shares during the period.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with our FREE daily email newsletter.